Geron (GERN)

• Market cap: $993M
• 1 day: -4.32%
• 5 days: -4.91%
• 1 month: -20.1%
• 3 months: 15.67%
• 6 months: 17.42%
• Year to date: 17.42%
• 1 year: -10.4%
• 5 years: -11.43%
• 10 years: -45.8%
• Sector: Healthcare
• Industry: Biotechnology

About: Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Employees: 258